



# Infectious Diseases Working Party

**Chair:** Rafael de la Camara  
**Statistician:** Gloria Tridello  
**Study Coordinator Lead:** Nina Knelange  
**Data Manager:** Inge Verheggen  
**Secretary:** Dina Averbuch  
**Study Coordinator:** Lotus Wendel  
**Data Entry Clerk:** Juana Schwartz Mota

## IDWP in 2023

### Major Achievements

At the 49<sup>th</sup> EBMT Annual Meeting in Paris, France, the IDWP session was at the 4<sup>th</sup> place among the top 10 most attended in-person sessions! The IDWP session attracted 600 in-person attendees, 461 live-stream participations and 177 on-demand watches. This is the second year of the IDWP session being one of the most attended sessions at the annual EBMT meeting.

In 2023, the new EBMT Registry was launched, with more room for questions pertaining to infectious complications. This will increase the quantity and quality of infection-related data and facilitate the performance of feasibility assessments and registry-based studies.

In September 2023, the IDWP organized the workshop "Definition of infectious complications", as part of the EBMT Practice Harmonization Workshops in Lille, France. Under the leadership of Per Ljungman and Rafael de la Camara, this workshop aims to achieve consistency in definitions and applicability of infectious complications, specifically in HSCT patients, and harmonization in the reporting of infections within the new Registry.

In November 2023, we welcomed the IDWP community in Athens, Greece, for the 26<sup>th</sup> IDWP-EBMT Educational Course, with 118 attendees from 18 different countries. 75.7% afterwards rated it as an excellent course!

Overall, in 2023, the IDWP had 19 publications and 7 oral and 3 poster presentations at international conferences.

### Principal currently ongoing studies

- Infections management following CAR-T (*D. Averbuch*)
- Fusarium infections in allo-HSCT (*D. Averbuch*)
- Role of EBV sero-status on outcome after PTCy-haplo-HCT (*J. Styczynski*)
- HIV-positive patients undergoing HSCT (*A. Paviglianti*)
- Neglected Tropical Diseases (NTDs) in HCT (HSCT and CAR-T) in adults and children treated within EBMT centres (*J. Snowden*)
- Non-cryopreserved hematopoietic stem cells for autologous HSCT (*E. Snarski*)

### Key Publications in the past year

1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Teh BW et al. 2024. Lancet Infect Dis. IF56.3 DOI:10.1016/S1473-3099(23)00377-8
2. Decrease of lethal infectious complications in the context of causes of death (COD) after HCT. Styczynski J et al. 2023. BMT IF4.8 DOI:10.1038/s41409-023-01998-2
3. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allo-HCT. Penack O et al. 2024. Lancet eClinM IF15.1 DOI:10.1016/j.eclinm.2023.102393
4. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, HCT and CAR-T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Cesaro S et al. 2023. Leukemia IF11.4 DOI:10.1038/s41375-023-01938-5
5. Improved outcomes over time and higher mortality in CMV seropositive allo-HCT patients with COVID-19. Ljungman P et al. 2023. Front Immunol. IF8.8 DOI:10.3389/fimmu.2023.1125824
6. Risk factors for a severe disease course in children with SARS-CoV-2 infection following HCT in the pre-Omicron period. Averbuch D et al. 2023. BMT IF4.8 DOI:10.1038/s41409-023-01941-5
7. Upper and/or lower respiratory tract infection caused by human metapneumovirus after allo-HCT. JL Piñana Sanchez et al. 2024. J Infect Dis. IF7.8 DOI:10.1093/infdis/jjad268
8. Pneumocystis pneumonia after allo-HCT. Robin C et al. 2024. Transplant Cell Ther. IF3.2 DOI:10.1016/j.jct.2023.11.017.
9. Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT. Styczynski J et al. 2024. BMT IF 4.8 DOI:10.1038/s41409-023-02129-7.
10. Infection prevention practices among EBMT HCT centers. Yeshurun M et al. 2023. BMT IF4.8 DOI:10.1038/s41409-023-01916-6.
11. New trends in the management of cytomegalovirus infection after allo-HCT. Cesaro S et al. 2023. BMT IF4.8 DOI:10.1038/s41409-022-01863-8.

### Planned for 2024

### Studies

- The effect of antimicrobial prophylaxis on early post-transplant mortality in patients with MM and Lymphoma undergoing high-dose chemotherapy and Auto-HCT (*M. Yeshurun*)
- Post-transplant hemorrhagic cystitis in allogeneic HCT patients (*S. Cesaro*)
- ICU organization and ICU admission after HCT with special emphasis on infectious causes (*J. Drozd-Sokolowska*)

### Educational activities

27<sup>th</sup> IDWP-EBMT Educational Course (7-9 November 2024, Geneva, Switzerland)

Contact IDWP:  
idwp.ebmt@lumc.nl

## 50<sup>th</sup> Annual Meeting of EBMT (14-17 April 2024, Glasgow, Scotland)

### IDWP-organised sessions

**IDWP Business Meeting** Mon, April 15, 12.45-14.00h

**IDWP Working Party Session** Mon, April 15, 9.00-10.15h

*Chair: Rafael de la Camara*

1. *A. Piekarska* – Impact and management of Clostridioides difficile in HCT patients
2. *R. Chemaly* – CMV management based on T cell immunity:  
Time to incorporate in the routine care for allogeneic HCT patients?
3. *D. Averbuch* – How can we decrease antibiotic exposure in patients following HSCT?
4. *M. Mikulska* – Top 10 papers in HSCT infections (2023-2024)

Practice Harmonization Day 3 (HM3): Tue, April 16, 14.30-15.45h

### IDWP harmonization workshop

*Chair: Per Ljungman*

HM3-1 *J.L. Piñana Sanchez* – Harmonizing infection definitions

HM3-2 *D. Averbuch* – Bloodstream infection

HM3-3 Q&A

### IDWP-affiliated oral presentations

Oral Sessions 3 (OS03): Wed, April 15, 11.00-12.15h

### Infection – diagnosis, management and outcome

OS3-03 *K. Perruccio* – Incidence and outcome of HHV-6 encephalitis in HLA-haploidentical stem cell transplant recipients:

A prospective analysis of the IDWP-EBMT

OS3-05 *M. Faraci* – Retrospective study on the incidence and outcome of adenovirus infections in patients after haploidentical stem cell transplant:  
A study of the IDWP-EBMT

### Other infection-related sessions

• Industry Symposium (IS10): **Takeda** April 14, 10.30-12.00h

#### Advancing patient outcomes in CMV management

• Industry Symposium (IS11): **Kite-Gilead** April 14, 12.30-14.00h

#### IFI and antifungal treatment challenges: Managing resistance and DDIs

• Industry Symposium (IS18): **MSD** April 14, 14.30-16.00h

#### What's New in CMV Management in HSCT? Latest Clinical Advances

• Industry Symposium (IS20): **Pfizer** April 14, 14.30-16.00h

#### Pfizer Promotional Symposium: Suspect, test and treat mould infections and respiratory virus-associated infections in the haematology setting

• Meet the Expert (MTE-3): **Johan Maertens** April 15, 07.45-08.45h

#### How I manage invasive fungal infections

• Pharmacists Day (Pharm2): **Supportive care** April 15, 11.00-12.15h

• Industry Theatre (IT2): **Takeda** April 15, 13.10-13.45h

#### Beyond viremia clearance: 360 perspectives in post-transplant CMV infection

• Data Management (DM4): April 15, 17.30-18.20h

#### How do I? Report infectious complications after Treatment

• Nurses Group (NG16): **Infections** April 16, 14.30-16.00h

• Educational (E06): April 16, 16.30-18.00h

#### Management of infectious disease

• Joint sessions (JS06): April 17, 10.30-11.45h

#### EBMT/BSH/BSBMTCT | Covid

### IDWP-affiliated poster presentations

P080 *E. Snarski* – Use of non-cryopreserved hematopoietic stem cells for autologous HSCT in adults

A156 *J.L. Piñana Sanchez* – Descriptive analyses of pulmonary function changes before and after Covid-19 in allogeneic HSCT recipients

A163 *M. Stamouli* – Non-tuberculous mycobacterial infections in HSCT recipients

A183 *J.L. Piñana Sanchez* – SARS-CoV-2 cycle threshold levels and Covid-19 outcome in allogeneic stem cell transplantation

A203 *M. Mikulska* – Real life management of antibiotic therapy in HSCT recipients – focus on de-escalation in pre-engraftment neutropenia